Highlights and Quick Summary
- SG&A Expenses for the quarter ending February 28, 2022 was $11.7 Million (a 10.05% increase compared to previous quarter)
- Year-over-year quarterly SG&A Expenses increased by 3.52%
- Annual SG&A Expenses for 2021 was $41.5 Million (a 16.92% increase from previous year)
- Annual SG&A Expenses for 2020 was $35.5 Million (a 14.25% increase from previous year)
- Annual SG&A Expenses for 2019 was $31 Million (a 159.18% increase from previous year)
- Twelve month SG&A Expenses ending February 28, 2022 was $45.3 Million (a 6.39% increase compared to previous quarter)
- Twelve month trailing SG&A Expenses increased by 20.86% year-over-year
Trailing SG&A Expenses for the last four month:
28 Feb '22 | 30 Nov '21 | 31 Aug '21 | 31 May '21 |
---|---|---|---|
$45.3 Million | $42.6 Million | $40.8 Million | $37.5 Million |
Visit stockrow.com/OGI
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical SG&A Expenses of Organigram Holdings Inc.
Most recent SG&A Expensesof OGI including historical data for past 10 years.Interactive Chart of SG&A Expenses of Organigram Holdings Inc.
Organigram Holdings Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2022 | $11.67 | – | – | – | – |
2021 | $10.6 | $11.8 | $11.27 | $8.94 | $41.48 |
2020 | $8.76 | $8.54 | $8.12 | $11.62 | $35.47 |
2019 | $8.35 | $12.17 | $8.29 | $7.3 | $31.05 |
2018 | – | – | – | $4.2 | $11.98 |
2017 | – | – | – | – | $5.82 |
2016 | – | – | – | – | $3.11 |
Business Profile of Organigram Holdings Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic